Journal List > Tuberc Respir Dis > v.71(1) > 1001642

TOOLS
Shin: Clinical Year-in-Review of Chronic Obstructive Pulmonary Disease in Korea
Review
Tuberculosis and Respiratory Diseases

Tuberculosis and Respiratory Diseases 2011; 71(1): 1-7.

Published online: 31 July 2011

DOI: https://doi.org/10.4046/trd.2011.71.1.1

Clinical Year-in-Review of Chronic Obstructive Pulmonary Disease in Korea

Kyeong-Cheol Shin, M.D., Ph.D.

Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.

Address for correspondence: Kyeong-Cheol Shin, M.D., Ph.D. Department of Internal Medicine, Yeungnam University College of Medicine, Daemyeong 5-dong, Nam-gu, Daegu 705-717, Korea. Phone: 82-53-620-3850, Fax: 82-53-654-8386, shin1014@ynu.ac.kr

Received 28 May 2011       Accepted 2 June 2011

Copyright © 2011. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Abstract

Many findings suggest that chronic obstructive pulmonary disease (COPD) imposes an enormous burden on patients, health-care professionals and society. COPD contributes to morbidity and mortality and to a significant use of health-care resources. In spite of a higher prevalence of COPD in Korea, the result of COPD treatment is not effective. The purpose of this article was to review recent advances in the study of COPD in Korea with the aim of improving effective management. This review highlights articles pertaining to the following topics; prevalence, assessment of COPD, risk factors for hospitalization, co-morbid diseases, phenotypes, and treatment issues.

Keywords: Pulmonary Disease, Chronic Obstructive, Prevalence, Patient Readmission, Comorbidity, Phenotype

References

1. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology. 2011. 16:659–665.
2. Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lee JH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med. 2005. 172:842–847.
3. Lee S, Lee JS, Song JW, Choi CM, Shim TS, Kim TB, et al. Validation of the Korean version of chronic obstructive pulmonary disease assessment test (CAT) and Dyspnea-12 questionnaire. Tuberc Respir Dis. 2010. 69:171–176.
4. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004. 350:1005–1012.
5. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009. 34:648–654.
6. Stoller JK, Ferranti R, Feinstein AR. Further specification and evaluation of a new clinical index for dyspnea. Am Rev Respir Dis. 1986. 134:1129–1134.
7. Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax. 2010. 65:21–26.
8. Kim MH, Lee K, Kim KU, Park HK, Jeon DS, Kim YS, et al. Risk factors associated with frequent hospital readmissions for exacerbation of COPD. Tuberc Respir Dis. 2010. 69:243–249.
9. Douglas SL, Daly BJ, Gordon N, Brennan PF. Survival and quality of life: short-term versus long-term ventilator patients. Crit Care Med. 2002. 30:2655–2662.
10. National Heart, Lung and Blood Institute; National Institutes of Health. Morbidity and mortality: 2007 chart book on cardiovascular, lung and blood diseases [internet]. 2007. cited 2010 Oct 14. Bethesda, MD: National Institutes of Health;Available from: http://www.nhlbi.nih.gov/resources/docs/07a-chtbk.pdf.
11. Jeong SW, Lee JH, Choi KJ, Hwangbo Y, Kim YY, Lee YJ, et al. Comparisons of clinical characteristics and outcomes in COPD patients hospitalized with community-acquired pneumonia and acute exacerbation. Tuberc Respir Dis. 2010. 69:31–38.
12. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995. 152:S77–S121.
13. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [internet]. Global Initiative for Chronic Obstructive Lung disease (GOLD). c2009. cited 2009 Nov 18. place unknown: GOLD;Available from: http//www.goldcopd.org.
14. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987. 106:196–204.
15. Kwon YS, Chi SY, Shin HJ, Kim EY, Yoon BK, Ban HJ, et al. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Korean Med Sci. 2010. 25:1487–1491.
16. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax. 2005. 60:605–609.
17. Jung HS, Lee JH, Chun EM, Moon JW, Chang JH. Predictors of long-term mortality after hospitalization for acute exacerbation of COPD. Tuberc Respir Dis. 2006. 60:205–214.
18. Barberà JA, Riverola A, Roca J, Ramirez J, Wagner PD, Ros D, et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994. 149:423–429.
19. Santos S, Peinado VI, Ramírez J, Melgosa T, Roca J, Rodriguez-Roisin R, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J. 2002. 19:632–638.
20. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992. 4:361–368.
21. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993. 82:513–520.
22. Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest. 2006. 130:326–333.
23. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988. 332:411–415.
24. Allen SW, Chatfield BA, Koppenhafer SA, Schaffer MS, Wolfe RR, Abman SH. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis. 1993. 148:519–522.
25. Ryu YJ, Chun EM, Lee JH, Chang JH. Prevalence of depression and anxiety in outpatients with chronic airway lung disease. Korean J Intern Med. 2010. 25:51–57.
26. Crockett AJ, Cranston JM, Moss JR, Alpers JH. The impact of anxiety, depression and living alone in chronic obstructive pulmonary disease. Qual Life Res. 2002. 11:309–316.
27. Dahlén I, Janson C. Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Chest. 2002. 122:1633–1637.
28. Jo KW, Ra SW, Chae EJ, Seo JB, Kim NK, Lee JH, et al. Three phenotypes of obstructive lung disease in the elderly. Int J Tuberc Lung Dis. 2010. 14:1481–1488.
29. Viegi G, Matteelli G, Angino A, Scognamiglio A, Baldacci S, Soriano JB, et al. The proportional Venn diagram of obstructive lung disease in the Italian general population. Chest. 2004. 126:1093–1101.
30. Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, et al. Predictors of pulmonary function response to treatment with salmeterol/fluticasone in patients with chronic obstructive pulmonary disease. J Korean Med Sci. 2011. 26:379–385.
31. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000. 320:1297–1303.
32. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000. 343:1902–1909.
33. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002. 166:1084–1091.
34. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007. 356:775–789.
35. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD guidelines Group of the Standards of Care Committee of the BTS. Thorax. 1997. 52:Suppl 5. S1–S28.
36. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax. 2003. 58:654–658.
37. Lee JH, Lee YK, Kim EK, Kim TH, Huh JW, Kim WJ, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med. 2010. 104:542–549.
38. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med. 1991. 114:216–223.
TOOLS
Similar articles